General MedicationsSUBCUTANEOUSStandard
EGRIFTA
TESAMORELIN ACETATE
Standard Dose
EQ 2MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview EGRIFTA is listed in Drugs@FDA under application 022505 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TESAMORELIN ACETATE Form and strength POWDER;SUBCUTANEOUS - EQ 2MG BASE/VIAL Sponsor THERATECHNOLOGIES Submission history Latest submission status date: 2025-03-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview EGRIFTA is listed in Drugs@FDA under application 022505 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TESAMORELIN ACETATE Form and strength POWDER;SUBCUTANEOUS - EQ 2MG BASE/VIAL Sponsor THERATECHNOLOGIES Submission history Latest submission status date: 2025-03-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.